RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Murali Yallapu to Mice, Nude

This is a "connection" page, showing publications Murali Yallapu has written about Mice, Nude.
Connection Strength

0.716
  1. Hatami E, Nagesh PKB, Jaggi M, Chauhan SC, Yallapu MM. Gambogic acid potentiates gemcitabine induced anticancer activity in non-small cell lung cancer. Eur J Pharmacol. 2020 Dec 05; 888:173486.
    View in: PubMed
    Score: 0.152
  2. Nagesh PKB, Chowdhury P, Hatami E, Kumari S, Kashyap VK, Tripathi MK, Wagh S, Meibohm B, Chauhan SC, Jaggi M, Yallapu MM. Cross-Linked Polyphenol-Based Drug Nano-Self-Assemblies Engineered to Blockade Prostate Cancer Senescence. ACS Appl Mater Interfaces. 2019 Oct 23; 11(42):38537-38554.
    View in: PubMed
    Score: 0.143
  3. Yallapu MM, Chauhan N, Othman SF, Khalilzad-Sharghi V, Ebeling MC, Khan S, Jaggi M, Chauhan SC. Implications of protein corona on physico-chemical and biological properties of magnetic nanoparticles. Biomaterials. 2015 Apr; 46:1-12.
    View in: PubMed
    Score: 0.103
  4. Yallapu MM, Khan S, Maher DM, Ebeling MC, Sundram V, Chauhan N, Ganju A, Balakrishna S, Gupta BK, Zafar N, Jaggi M, Chauhan SC. Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer. Biomaterials. 2014 Oct; 35(30):8635-48.
    View in: PubMed
    Score: 0.099
  5. Chauhan N, Maher DM, Hafeez BB, Mandil H, Singh MM, Yallapu MM, Jaggi M, Chauhan SC. Ormeloxifene nanotherapy for cervical cancer treatment. Int J Nanomedicine. 2019; 14:7107-7121.
    View in: PubMed
    Score: 0.036
  6. Chauhan N, Maher DM, Yallapu MM, B Hafeez B, Singh MM, Chauhan SC, Jaggi M. A triphenylethylene nonsteroidal SERM attenuates cervical cancer growth. Sci Rep. 2019 07 29; 9(1):10917.
    View in: PubMed
    Score: 0.035
  7. Massey AE, Sikander M, Chauhan N, Kumari S, Setua S, Shetty AB, Mandil H, Kashyap VK, Khan S, Jaggi M, Yallapu MM, Hafeez BB, Chauhan SC. Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment. Nanomedicine. 2019 08; 20:102027.
    View in: PubMed
    Score: 0.035
  8. Kumar BNP, Puvvada N, Rajput S, Sarkar S, Mahto MK, Yallapu MM, Pathak A, Emdad L, Das SK, Reis RL, Kundu SC, Fisher PB, Mandal M. Targeting of EGFR, VEGFR2, and Akt by Engineered Dual Drug Encapsulated Mesoporous Silica-Gold Nanoclusters Sensitizes Tamoxifen-Resistant Breast Cancer. Mol Pharm. 2018 07 02; 15(7):2698-2713.
    View in: PubMed
    Score: 0.033
  9. Sikander M, Hafeez BB, Malik S, Alsayari A, Halaweish FT, Yallapu MM, Chauhan SC, Jaggi M. Cucurbitacin D exhibits potent anti-cancer activity in cervical cancer. Sci Rep. 2016 11 08; 6:36594.
    View in: PubMed
    Score: 0.029
  10. Khan S, Chauhan N, Yallapu MM, Ebeling MC, Balakrishna S, Ellis RT, Thompson PA, Balabathula P, Behrman SW, Zafar N, Singh MM, Halaweish FT, Jaggi M, Chauhan SC. Nanoparticle formulation of ormeloxifene for pancreatic cancer. Biomaterials. 2015; 53:731-43.
    View in: PubMed
    Score: 0.026
  11. Khan S, Ebeling MC, Zaman MS, Sikander M, Yallapu MM, Chauhan N, Yacoubian AM, Behrman SW, Zafar N, Kumar D, Thompson PA, Jaggi M, Chauhan SC. MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer. Oncotarget. 2014 Sep 15; 5(17):7599-609.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support